These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 23857604

  • 1. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 2. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X, Pastan I, Bigner DD, Chandramohan V.
    Receptors Clin Investig; 2016 Sep 01; 3(4):. PubMed ID: 28286803
    [Abstract] [Full Text] [Related]

  • 3. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Appl Microbiol Biotechnol; 2017 Apr 01; 101(7):2747-2766. PubMed ID: 28013405
    [Abstract] [Full Text] [Related]

  • 4. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
    Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Int J Cancer; 2013 May 15; 132(10):2339-48. PubMed ID: 23115013
    [Abstract] [Full Text] [Related]

  • 5. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.
    J Immunother Cancer; 2019 May 29; 7(1):142. PubMed ID: 31142380
    [Abstract] [Full Text] [Related]

  • 6. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
    Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD.
    Invest New Drugs; 2016 Apr 29; 34(2):149-58. PubMed ID: 26728879
    [Abstract] [Full Text] [Related]

  • 7. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD.
    Nucl Med Biol; 2012 Jan 29; 39(1):23-34. PubMed ID: 21958852
    [Abstract] [Full Text] [Related]

  • 8. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
    Chandramohan V, Bigner DD.
    Oncoimmunology; 2013 Dec 01; 2(12):e26852. PubMed ID: 24498557
    [Abstract] [Full Text] [Related]

  • 9. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
    Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V.
    Sci Transl Med; 2023 Feb 08; 15(682):eabn5649. PubMed ID: 36753564
    [Abstract] [Full Text] [Related]

  • 10. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
    Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I.
    Proc Natl Acad Sci U S A; 1996 Dec 10; 93(25):14815-20. PubMed ID: 8962138
    [Abstract] [Full Text] [Related]

  • 11. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD.
    J Neurooncol; 2018 Jul 10; 138(3):489-498. PubMed ID: 29564747
    [Abstract] [Full Text] [Related]

  • 12. Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
    Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, Månsson JE, Pastan IH, Bigner DD.
    MAbs; 2013 Jul 10; 5(5):748-62. PubMed ID: 23924792
    [Abstract] [Full Text] [Related]

  • 13. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, Kesari S, Boothman DA, Habib AA.
    Oncogene; 2014 Aug 14; 33(33):4253-64. PubMed ID: 24077285
    [Abstract] [Full Text] [Related]

  • 14. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
    Wei JW, Cui JQ, Zhou X, Fang C, Tan YL, Chen LY, Yang C, Liu M, Kang CS.
    Cancer Lett; 2016 Sep 28; 380(1):1-9. PubMed ID: 27317648
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
    Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD.
    Cell Growth Differ; 1995 Oct 28; 6(10):1251-9. PubMed ID: 8845302
    [Abstract] [Full Text] [Related]

  • 16. A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.
    Meng J, Liu Y, Gao S, Lin S, Gu X, Pomper MG, Wang PC, Shan L.
    Cancer Biol Ther; 2015 Oct 28; 16(12):1764-74. PubMed ID: 26467217
    [Abstract] [Full Text] [Related]

  • 17. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.
    Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H.
    Cancer Res; 2010 Aug 01; 70(15):6303-12. PubMed ID: 20647323
    [Abstract] [Full Text] [Related]

  • 18. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 01; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 19. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, Kaur B, Caligiuri MA, Yu J.
    Sci Rep; 2015 Jul 09; 5():11483. PubMed ID: 26155832
    [Abstract] [Full Text] [Related]

  • 20. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH.
    PLoS One; 2014 Jul 09; 9(4):e94281. PubMed ID: 24722266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.